Jessica Nye

Researchers evaluated the diagnostic accuracy of the CDSS 2.0 to aid clinicians in headache diagnosis.

Researchers compared the safety and efficacy of drugs indicated for preventing migraine.

Cerebral palsy pain can negatively affect an individual’s earnings and lower access to full-time employment.

Researchers sought to evaluate long-term efficacy, safety, and tolerability of fremanezumab among patients with high-frequency episodic migraine or chronic migraine who had a history of 3 or more therapeutic failures.

A meta-analysis evaluated longitudinal change in placebo response in clinical trials for migraine prevention.

Researchers evaluated the suicide risk for patients with chronic non-cancer pain and a co-occurring opioid use disorder.

In a systematic review and meta-analysis, researchers evaluated whether online pain management programs are effective in the setting of chronic pain.

Researchers evaluated the effectiveness and safety of greater occipital nerve blockade for patients with cluster headache.

Researchers sought to assess the views and experiences of individuals currently, previously, and never taking cannabinoids for chronic pain to inform future research.

Researchers explored whether those with chronic pain who showed greater pain acceptance mitigated the relationship between pain severity, its perceived burden, and suicidal ideation.

Researchers sought to assess whether the presence of migraine affects FGF-21 and GDF-15 serum levels, and the relationship of these cytokines with patients’ clinical parameters.

Researchers investigated pregabalin use in post-traumatic peripheral neuropathic pain compared with a placebo.

Researchers investigated the effects of virtual reality intervention on pain reduction in pediatric patients undergoing venipuncture.

Researchers sought to determine how psychological distress, pain intensity, and social support affect lack of life control and interference.

Researchers investigated the relationship between neuropathic pain and pain duration in patients with low back pain.

Patients receiving the IVIG product on a 15-minute rate escalation
protocol had low rates of headache and migraine for both the 5% and 10% formulations.